ERBB2 and cancer: Initially demonstrated to selectively transduce HER2-positive cells, it has also been extended to in vivo CAR-T cell engineering, where bsAb-redirected SINV-LVs could efficiently generate functional CAR-T cells in immunodeficient mice, offering a promising platform for personalized cancer immunotherapy [117,118].